vs
Side-by-side financial comparison of Hologic (HOLX) and Trade Desk (The) (TTD). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $846.8M, roughly 1.2× Trade Desk (The)). Trade Desk (The) runs the higher net margin — 22.1% vs 17.1%, a 5.0% gap on every dollar of revenue. On growth, Trade Desk (The) posted the faster year-over-year revenue change (14.3% vs 2.5%). Trade Desk (The) produced more free cash flow last quarter ($285.3M vs $215.2M). Over the past eight quarters, Trade Desk (The)'s revenue compounded faster (31.3% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
The Trade Desk, Inc. is an American multinational technology company that specializes in real-time programmatic marketing automation technologies, products, and services, designed to personalize digital content delivery to users.
HOLX vs TTD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $846.8M |
| Net Profit | $179.1M | $186.9M |
| Gross Margin | 56.0% | 80.7% |
| Operating Margin | 22.6% | 30.3% |
| Net Margin | 17.1% | 22.1% |
| Revenue YoY | 2.5% | 14.3% |
| Net Profit YoY | -10.9% | 2.6% |
| EPS (diluted) | $0.79 | $0.39 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $846.8M | ||
| Q3 25 | $1.0B | $739.4M | ||
| Q2 25 | $1.0B | $694.0M | ||
| Q1 25 | $1.0B | $616.0M | ||
| Q4 24 | $1.0B | $741.0M | ||
| Q3 24 | $988.0M | $628.0M | ||
| Q2 24 | $1.0B | $584.5M | ||
| Q1 24 | $1.0B | $491.3M |
| Q4 25 | $179.1M | $186.9M | ||
| Q3 25 | $187.2M | $115.5M | ||
| Q2 25 | $194.9M | $90.1M | ||
| Q1 25 | $-17.4M | $50.7M | ||
| Q4 24 | $201.0M | $182.2M | ||
| Q3 24 | $178.6M | $94.2M | ||
| Q2 24 | $194.5M | $85.0M | ||
| Q1 24 | $169.9M | $31.7M |
| Q4 25 | 56.0% | 80.7% | ||
| Q3 25 | 55.6% | 78.1% | ||
| Q2 25 | 56.3% | 78.2% | ||
| Q1 25 | 37.5% | 76.8% | ||
| Q4 24 | 56.8% | 81.7% | ||
| Q3 24 | 56.4% | 80.5% | ||
| Q2 24 | 55.4% | 81.1% | ||
| Q1 24 | 53.3% | 78.9% |
| Q4 25 | 22.6% | 30.3% | ||
| Q3 25 | 22.6% | 21.8% | ||
| Q2 25 | 24.9% | 16.8% | ||
| Q1 25 | -0.7% | 8.8% | ||
| Q4 24 | 22.5% | 26.4% | ||
| Q3 24 | 23.3% | 17.3% | ||
| Q2 24 | 24.1% | 16.2% | ||
| Q1 24 | 20.7% | 5.8% |
| Q4 25 | 17.1% | 22.1% | ||
| Q3 25 | 17.8% | 15.6% | ||
| Q2 25 | 19.0% | 13.0% | ||
| Q1 25 | -1.7% | 8.2% | ||
| Q4 24 | 19.7% | 24.6% | ||
| Q3 24 | 18.1% | 15.0% | ||
| Q2 24 | 19.2% | 14.5% | ||
| Q1 24 | 16.7% | 6.4% |
| Q4 25 | $0.79 | $0.39 | ||
| Q3 25 | $0.84 | $0.23 | ||
| Q2 25 | $0.86 | $0.18 | ||
| Q1 25 | $-0.08 | $0.10 | ||
| Q4 24 | $0.87 | $0.36 | ||
| Q3 24 | $0.75 | $0.19 | ||
| Q2 24 | $0.82 | $0.17 | ||
| Q1 24 | $0.72 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $1.3B |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $5.2B | $2.5B |
| Total Assets | $9.2B | $6.2B |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | $1.3B | ||
| Q3 25 | $2.2B | $1.4B | ||
| Q2 25 | $1.9B | $1.7B | ||
| Q1 25 | $1.6B | $1.7B | ||
| Q4 24 | $2.0B | $1.9B | ||
| Q3 24 | $2.3B | $1.7B | ||
| Q2 24 | $2.4B | $1.5B | ||
| Q1 24 | $2.2B | $1.4B |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.6B | — |
| Q4 25 | $5.2B | $2.5B | ||
| Q3 25 | $5.0B | $2.6B | ||
| Q2 25 | $4.8B | $2.7B | ||
| Q1 25 | $4.6B | $2.7B | ||
| Q4 24 | $4.8B | $2.9B | ||
| Q3 24 | $5.1B | $2.6B | ||
| Q2 24 | $5.0B | $2.4B | ||
| Q1 24 | $4.8B | $2.2B |
| Q4 25 | $9.2B | $6.2B | ||
| Q3 25 | $9.0B | $5.9B | ||
| Q2 25 | $8.8B | $6.0B | ||
| Q1 25 | $8.5B | $5.7B | ||
| Q4 24 | $8.7B | $6.1B | ||
| Q3 24 | $9.2B | $5.5B | ||
| Q2 24 | $8.9B | $5.2B | ||
| Q1 24 | $8.7B | $4.7B |
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 0.53× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $311.6M |
| Free Cash FlowOCF − Capex | $215.2M | $285.3M |
| FCF MarginFCF / Revenue | 20.5% | 33.7% |
| Capex IntensityCapex / Revenue | 1.4% | 3.1% |
| Cash ConversionOCF / Net Profit | 1.28× | 1.67× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $795.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $311.6M | ||
| Q3 25 | $355.1M | $224.7M | ||
| Q2 25 | $343.3M | $165.0M | ||
| Q1 25 | $169.4M | $291.4M | ||
| Q4 24 | $189.3M | $199.4M | ||
| Q3 24 | $367.0M | $273.3M | ||
| Q2 24 | $405.8M | $81.3M | ||
| Q1 24 | $292.4M | $185.5M |
| Q4 25 | $215.2M | $285.3M | ||
| Q3 25 | $341.4M | $158.3M | ||
| Q2 25 | $330.5M | $119.8M | ||
| Q1 25 | $153.9M | $232.3M | ||
| Q4 24 | $172.5M | $179.2M | ||
| Q3 24 | $350.6M | $224.6M | ||
| Q2 24 | $385.3M | $59.1M | ||
| Q1 24 | $279.6M | $178.2M |
| Q4 25 | 20.5% | 33.7% | ||
| Q3 25 | 32.5% | 21.4% | ||
| Q2 25 | 32.3% | 17.3% | ||
| Q1 25 | 15.3% | 37.7% | ||
| Q4 24 | 16.9% | 24.2% | ||
| Q3 24 | 35.5% | 35.8% | ||
| Q2 24 | 38.1% | 10.1% | ||
| Q1 24 | 27.5% | 36.3% |
| Q4 25 | 1.4% | 3.1% | ||
| Q3 25 | 1.3% | 9.0% | ||
| Q2 25 | 1.3% | 6.5% | ||
| Q1 25 | 1.5% | 9.6% | ||
| Q4 24 | 1.6% | 2.7% | ||
| Q3 24 | 1.7% | 7.8% | ||
| Q2 24 | 2.0% | 3.8% | ||
| Q1 24 | 1.3% | 1.5% |
| Q4 25 | 1.28× | 1.67× | ||
| Q3 25 | 1.90× | 1.94× | ||
| Q2 25 | 1.76× | 1.83× | ||
| Q1 25 | — | 5.75× | ||
| Q4 24 | 0.94× | 1.09× | ||
| Q3 24 | 2.05× | 2.90× | ||
| Q2 24 | 2.09× | 0.96× | ||
| Q1 24 | 1.72× | 5.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
TTD
| Other | $427.2M | 50% |
| Non Us | $419.6M | 50% |
